Related references
Note: Only part of the references are listed.Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia
Sibasish Dolai et al.
CANCER RESEARCH (2016)
AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia
Donya Moradi Manesh et al.
BLOOD (2015)
Analysis of single mouse tumor response results from the Pediatric Preclinical Testing Program (PPTP)
Brendan Murphy et al.
CANCER RESEARCH (2015)
Evaluation of the Bcl-2 inhibitor ABT-199 in xenograft models of acute lymphoblastic leukemia by the pediatric preclinical testing program
Santi Suryani et al.
CANCER RESEARCH (2015)
Effective Targeting of the P53-MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia
Jennifer Richmond et al.
CLINICAL CANCER RESEARCH (2015)
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
Marina Konopleva et al.
HAEMATOLOGICA (2015)
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
Marina Konopleva et al.
HAEMATOLOGICA (2015)
Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia
Santi Suryani et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Efficacy of CPX-351, (Cytarabine: Daunorubicin) Liposome Injection, Against Acute Lymphoblastic Leukemia (ALL) Xenograft Models of the Pediatric Preclinical Testing Program
Hernan Carol et al.
PEDIATRIC BLOOD & CANCER (2015)
Initial Testing (Stage 1) of the PARP Inhibitor BMN 673 by the Pediatric Preclinical Testing Program: PALB2 Mutation Predicts Exceptional In Vivo Response to BMN 673
Malcolm A. Smith et al.
PEDIATRIC BLOOD & CANCER (2015)
A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells
Stephen M. F. Jamieson et al.
BIOCHEMICAL PHARMACOLOGY (2014)
Declining Childhood and Adolescent Cancer Mortality
Malcolm A. Smith et al.
CANCER (2014)
Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts
Santi Suryani et al.
CLINICAL CANCER RESEARCH (2014)
Pediatric Preclinical Testing Program (PPTP) Evaluation of the p53-MDM2 Antagonist MK-8242
M. Smith et al.
EUROPEAN JOURNAL OF CANCER (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
K. G. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Initial Testing (Stage 1) of the Polo-Like Kinase Inhibitor Volasertib (BI 6727), by the Pediatric Preclinical Testing Program
Richard Gorlick et al.
PEDIATRIC BLOOD & CANCER (2014)
Initial Testing (Stage 1) of the Histone Deacetylase Inhibitor, Quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program
Hernan Carol et al.
PEDIATRIC BLOOD & CANCER (2014)
Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program
Hernan Carol et al.
PEDIATRIC BLOOD & CANCER (2014)
Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program
Min H. Kang et al.
PEDIATRIC BLOOD & CANCER (2014)
Targeting BCL2 for the Treatment of Lymphoid Malignancies
Mary Ann Anderson et al.
SEMINARS IN HEMATOLOGY (2014)
Antibody therapy for pediatric leukemia
Aditi Vedi et al.
FRONTIERS IN ONCOLOGY (2014)
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia
Julia Etchin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
The Anti-CD19 Antibody-Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia
Hernan Carol et al.
CLINICAL CANCER RESEARCH (2013)
Targeting the Bcl-2 family for cancer therapy
Shibu Thomas et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2013)
New insights into drug development for pediatric solid tumors: what preclinical data justify clinical trials in pediatric cancer?
Peter J. Houghton
EXPERT REVIEW OF ANTICANCER THERAPY (2013)
New drugs for children and adolescents with cancer: the need for novel development pathways
Gilles Vassal et al.
LANCET ONCOLOGY (2013)
AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors
Elizabeth R. Plimack et al.
ONCOLOGIST (2013)
Initial Testing of the MDM2 Inhibitor RG7112 by the Pediatric Preclinical Testing Program
Hernan Carol et al.
PEDIATRIC BLOOD & CANCER (2013)
Initial testing (stage 1) of the phosphatidylinositol 3 kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program
C. Patrick Reynolds et al.
PEDIATRIC BLOOD & CANCER (2013)
Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program
Richard B. Lock et al.
PEDIATRIC BLOOD & CANCER (2013)
Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program
Stephen T. Keir et al.
PEDIATRIC BLOOD & CANCER (2013)
Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program
E. Anders Kolb et al.
PEDIATRIC BLOOD & CANCER (2013)
The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia
Roel Polak et al.
BLOOD (2012)
Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
Yoav H. Messinger et al.
BLOOD (2012)
Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study
Yael P. Mosse et al.
CLINICAL CANCER RESEARCH (2012)
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
S. K. Metzelder et al.
LEUKEMIA (2012)
Pharmacokinetic Modeling of an Induction Regimen for In Vivo Combined Testing of Novel Drugs against Pediatric Acute Lymphoblastic Leukemia Xenografts
Barbara Szymanska et al.
PLOS ONE (2012)
Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program
Richard Gorlick et al.
PEDIATRIC BLOOD & CANCER (2012)
Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program
Peter J. Houghton et al.
PEDIATRIC BLOOD & CANCER (2012)
Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program
Malcolm A. Smith et al.
PEDIATRIC BLOOD & CANCER (2012)
Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program
Peter J. Houghton et al.
PEDIATRIC BLOOD & CANCER (2012)
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling
E. Anders Kolb et al.
PEDIATRIC BLOOD & CANCER (2012)
Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program
Vandana Batra et al.
PEDIATRIC BLOOD & CANCER (2012)
Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program
Malcolm A. Smith et al.
PEDIATRIC BLOOD & CANCER (2012)
Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program
Peter J. Houghton et al.
PEDIATRIC BLOOD & CANCER (2012)
Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program
Min H. Kang et al.
PEDIATRIC BLOOD & CANCER (2012)
Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program
Richard B. Lock et al.
PEDIATRIC BLOOD & CANCER (2012)
Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program
Richard Gorlick et al.
PEDIATRIC BLOOD & CANCER (2012)
New markers for minimal residual disease detection in acute lymphoblastic leukemia
Elaine Coustan-Smith et al.
BLOOD (2011)
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer
Hernan Carol et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Pharmacokinetic-Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation
Harvey Wong et al.
CLINICAL CANCER RESEARCH (2011)
Mutations and Deletions of the TP53 Gene Predict Nonresponse to Treatment and Poor Outcome in First Relapse of Childhood Acute Lymphoblastic Leukemia
Jana Hof et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Challenging issues in pediatric oncology
Ching-Hon Pui et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
High drug attrition rates-where are we going wrong?
Lisa Hutchinson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104
Juliana Benito et al.
PLOS ONE (2011)
Initial Testing (Stage 1) of the IGF-1 Receptor Inhibitor BMS-754807 by the Pediatric Preclinical Testing Program
E. Anders Kolb et al.
PEDIATRIC BLOOD & CANCER (2011)
Initial Testing of Lenalidomide by the Pediatric Preclinical Testing Program
C. Patrick Reynolds et al.
PEDIATRIC BLOOD & CANCER (2011)
Initial Testing (Stage 1) of the Polyamine Analog PG11047 by the Pediatric Preclinical Testing Program
Malcolm A. Smith et al.
PEDIATRIC BLOOD & CANCER (2011)
Curaxins: Anticancer Compounds that Simultaneously Suppress NF-κB and Activate p53 by Targeting FACT
Alexander V. Gasparian et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study
Richard H. Ko et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias
William Blum et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group
Torsten Haferlach et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report
Maryam Fouladi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Recent Research Advances in Childhood Acute Lymphoblastic Leukemia
Ching-Hon Pui
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2010)
Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program
Peter J. Houghton et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Initial Testing (Stage 1) of the Multi-Targeted Kinase Inhibitor Sorafenib by the Pediatric Preclinical Testing Program
Stephen T. Keir et al.
PEDIATRIC BLOOD & CANCER (2010)
Phase I Study of Bortezomib Combined With Chemotherapy in Children With Relapsed Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Therapeutic Advances in Childhood Leukemia (TACL) Consortium
Yoav Messinger et al.
PEDIATRIC BLOOD & CANCER (2010)
Initial Testing (Stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program
E. Anders Kolb et al.
PEDIATRIC BLOOD & CANCER (2010)
Initial Testing (Stage 1) of the Akt Inhibitor GSK690693 by the Pediatric Preclinical Testing Program
Hernan Carol et al.
PEDIATRIC BLOOD & CANCER (2010)
IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer
Mads Gyrd-Hansen et al.
NATURE REVIEWS CANCER (2010)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation
Elena Razumovskaya et al.
EXPERIMENTAL HEMATOLOGY (2009)
Long-term Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia
Paul C. Nathan et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2009)
Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
Kirk R. Schultz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Next generation oncology drug development: opportunities and challenges
Martin E. Gutierrez et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Initial Testing (Stage 1) of Lapatinib by the Pediatric Preclinical Testing Program
Richard Gorlick et al.
PEDIATRIC BLOOD & CANCER (2009)
Initial Testing of Aplidin by the Pediatric Pre-Clinical Testing Program
Christopher L. Morton et al.
PEDIATRIC BLOOD & CANCER (2009)
Initial Testing (Stage 1) of the Kinesin Spindle Protein Inhibitor Ispinesib by the Pediatric Preclinical Testing Program
Hernan Carol et al.
PEDIATRIC BLOOD & CANCER (2009)
Initial Testing (Stage 1) of Vorinostat (SAHA) by the Pediatric Preclinical Testing Program
Nino Keshelava et al.
PEDIATRIC BLOOD & CANCER (2009)
Molecular characterization of the pediatric preclinical testing panel
Geoffrey Neale et al.
CLINICAL CANCER RESEARCH (2008)
Approved monoclonal antibodies for cancer therapy
Michael Boyiadzis et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program
Peter J. Houghton et al.
PEDIATRIC BLOOD & CANCER (2008)
Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program
John M. Maris et al.
PEDIATRIC BLOOD & CANCER (2008)
Initial testing of cisplatin by the pediatric preclinical testing program
Mimi Tajbakhsh et al.
PEDIATRIC BLOOD & CANCER (2008)
Initial testing of dasatinib by the Pediatric Preclinical Testing Program
E. Anders Kolb et al.
PEDIATRIC BLOOD & CANCER (2008)
Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the Pediatric Preclinical Testing Program
E. Anders Kolb et al.
PEDIATRIC BLOOD & CANCER (2008)
Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program
Malcolm A. Smith et al.
PEDIATRIC BLOOD & CANCER (2008)
Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
Peter J. Houghton et al.
PEDIATRIC BLOOD & CANCER (2008)
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
Guillermo Garcia-Manero et al.
BLOOD (2008)
The pediatric preclinical testing program: Description of models and early testing results
Peter J. Houghton et al.
PEDIATRIC BLOOD & CANCER (2007)
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations
Rama Krishna Kancha et al.
EXPERIMENTAL HEMATOLOGY (2007)
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: A Children's Oncology Group study
Terzah M. Horton et al.
CLINICAL CANCER RESEARCH (2007)
Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis
Craig C. Whiteford et al.
CANCER RESEARCH (2007)
Targeting apoptosis pathways in cancer therapy
IM Ghobrial et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development
JK Peterson et al.
EUROPEAN JOURNAL OF CANCER (2004)
Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors
NC Daw et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies
NLM Liem et al.
BLOOD (2004)
Regulatory approvals of pediatric oncology drugs: Previous experience and new initiatives
S Hirschfeld et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Protracted intermittent schedule of topotecan in children with refractory acute leukemia: A Pediatric Oncology Group study
WL Furman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
